Neuraxis, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuraxis, INC. (NRXS) on November 21, 2024, covering events occurring on November 15, 2024. The company is incorporated in Delaware and trades on the NYSE American. It is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and capital structure amendments.
Material Changes
The company executed a material modification to the rights of Series B Preferred Stock holders via Amendment No. 1 to the Certificate of Designation. Key changes include:
- Authorized Shares: Increased from 4,000,000 to 5,000,000 shares.
- Dividend Extension: The right to receive dividends at an annual rate of 8.5% was extended by 18 months, moving the expiration date from June 30, 2025, to December 31, 2026.
- Voting Rights: Amended to allow holders to cast votes equal to the number of Common Stock shares into which their Series B Preferred Stock is convertible, based on a conversion price of $3.80 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors beyond the standard incorporation by reference of the amendment text. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the full text of Exhibit 3.1 (Amendment No. 1) for detailed legal terms regarding the Series B Preferred Stock.
- Confirm the impact of the increased authorized share count on potential dilution.
- Review the implications of the extended 8.5% dividend obligation on future cash flow requirements.
- Assess how the new voting rights structure affects the balance of power between Series B holders and Common Stockholders.